Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
37.95 SEK | +1.20% | +24.17% | +45.11% |
Apr. 18 | Transcript : Hansa Biopharma AB, Q1 2024 Earnings Call, Apr 18, 2024 | |
Apr. 18 | Hansa Biopharma AB Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
Sales 2024 * | 239M 22.15M | Sales 2025 * | 343M 31.73M | Capitalization | 2.37B 219M |
---|---|---|---|---|---|
Net income 2024 * | -735M -68.06M | Net income 2025 * | -712M -65.93M | EV / Sales 2024 * | 11.9 x |
Net Debt 2024 * | 474M 43.89M | Net Debt 2025 * | 733M 67.91M | EV / Sales 2025 * | 9.05 x |
P/E ratio 2024 * |
-3.25
x | P/E ratio 2025 * |
-3.86
x | Employees | 166 |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 88.64% |
Latest transcript on Hansa Biopharma AB
1 day | +6.59% | ||
1 week | +28.87% | ||
Current month | +29.58% | ||
1 month | +23.36% | ||
3 months | +9.20% | ||
6 months | +39.51% | ||
Current year | +43.13% |
Managers | Title | Age | Since |
---|---|---|---|
Søren Tulstrup
CEO | Chief Executive Officer | 59 | 18-03-19 |
Hitto Kaufmann
CTO | Chief Tech/Sci/R&D Officer | 53 | Nov. 30 |
Achim Kaufhold
CTO | Chief Tech/Sci/R&D Officer | 66 | 20-05-28 |
Members of the board | Title | Age | Since |
---|---|---|---|
Director/Board Member | 73 | 18-05-28 | |
Peter Nicklin
CHM | Chairman | 61 | 22-06-29 |
Mats Blom
BRD | Director/Board Member | 59 | 19-05-21 |
Date | Price | Change | Volume |
---|---|---|---|
24-05-15 | 38.02 | +1.39% | 75 405 |
24-05-14 | 37.5 | +6.59% | 428,894 |
24-05-13 | 35.18 | +10.14% | 556,316 |
24-05-10 | 31.94 | +4.31% | 162,005 |
24-05-08 | 30.62 | +5.22% | 181,265 |
Delayed Quote Nasdaq Stockholm, May 15, 2024 at 03:22 am EDT
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
+43.13% | 219M | |
+29.03% | 49.18B | |
-0.10% | 42.11B | |
+43.45% | 40.37B | |
-5.26% | 28.85B | |
+11.48% | 26.09B | |
-22.74% | 18.71B | |
+9.06% | 13.26B | |
+30.01% | 12.32B | |
-1.51% | 11.99B |
- Stock Market
- Equities
- HNSA Stock